» Articles » PMID: 21446008

A Snapshot of the Expression Signature of Androgen Receptor Splicing Variants and Their Distinctive Transcriptional Activities

Overview
Journal Prostate
Date 2011 Mar 30
PMID 21446008
Citations 128
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The diversity and complexity of the human androgen receptor (AR) splicing variants are well appreciated but not fully understood. The goal of this study is to generate a comprehensive expression signature of AR variants in castration-resistant prostate cancer (CRPC), and to address the relative importance of the individual variants in conferring the castration-resistant phenotype.

Methods: A modified RNA amplification method, termed selective linear amplification of sense RNA, was developed to amplify all AR transcripts containing AR exon 3 in CRPC specimens, which were profiled using tiling expression microarrays. Coding sequences for the AR variants were cloned into expression vectors and assessed for their transcriptional activities. Quantitative RT-PCR was used to determine their in vivo expression patterns in an expanded set of clinical specimens.

Results: In addition to expression peaks in AR intron 3, a novel AR exon, termed exon 9, was discovered. Exon 9 was spliced into multiple novel AR variants. Different AR splicing variants were functionally distinctive, with some demonstrating constitutive activity while others were conditionally active. Conditionally active AR-Vs may activate AR signaling depending on the cellular context. Importantly, AR variant functions did not appear to depend on the full-length AR.

Conclusions: This study provided the first unbiased snapshot of the AR variant signature consisting of multiple AR variants with distinctive functional properties, directly in CRPC specimens. Study findings suggest that the aggregate function of multiple AR variants may confer a castration-resistant phenotype independent of the full-length AR.

Citing Articles

Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 (IGF2BP2) Promotes Castration-Resistant Prostate Cancer Progression by Regulating AR-V7 mRNA Stability.

Saini T, Srivastava D, Raut R, Mishra P, Misra A Cancer Rep (Hoboken). 2025; 8(2):e70096.

PMID: 39948708 PMC: 11825379. DOI: 10.1002/cnr2.70096.


Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?.

Srivastava T, Dhar R, Karmakar S Reprod Biol Endocrinol. 2025; 23(1):9.

PMID: 39833837 PMC: 11744844. DOI: 10.1186/s12958-024-01338-z.


N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.

Chen Y, Lan T Front Pharmacol. 2024; 15:1451957.

PMID: 39359255 PMC: 11444995. DOI: 10.3389/fphar.2024.1451957.


Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics.

Effah W, Khalil M, Hwang D, Miller D, Narayanan R Steroids. 2024; 210:109486.

PMID: 39111362 PMC: 11380798. DOI: 10.1016/j.steroids.2024.109486.


SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.

Yi Q, Han X, Yu H, Chen H, Qiu D, Su J Oncogene. 2024; 43(20):1522-1533.

PMID: 38532114 DOI: 10.1038/s41388-024-02944-2.


References
1.
Kerkhoven R, Sie D, Nieuwland M, Heimerikx M, de Ronde J, Brugman W . The T7-primer is a source of experimental bias and introduces variability between microarray platforms. PLoS One. 2008; 3(4):e1980. PMC: 2292241. DOI: 10.1371/journal.pone.0001980. View

2.
Knudsen K, Scher H . Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009; 15(15):4792-8. PMC: 2842118. DOI: 10.1158/1078-0432.CCR-08-2660. View

3.
Guo Z, Yang X, Sun F, Jiang R, Linn D, Chen H . A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69(6):2305-13. PMC: 2672822. DOI: 10.1158/0008-5472.CAN-08-3795. View

4.
Bova G, Fox W, Epstein J . Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol. 1993; 6(2):201-7. View

5.
Andersen R, Mawji N, Wang J, Wang G, Haile S, Myung J . Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010; 17(6):535-46. DOI: 10.1016/j.ccr.2010.04.027. View